ITeos to Participate in Upcoming Investor Conferences
ITeos to Participate in Upcoming Investor Conferences
A live webcast of the conference presentation will be available on the Investors section of the company's website at . An archived replay will be available for approximately 30 days following the presentation.WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December:
WATERTOWN，馬薩諸塞州和比利時GOSSELIES，2024年11月26日（環球新聞社）-- iteos therapeutics公司（納斯達克股票代碼：ITOS），一家臨床階段的生物製藥公司，致力於開拓新一代免瘤治療藥物的發現和開發，今天宣佈公司管理層將參加12月的兩場即將舉行的會議：
7Th Annual Evercore HealthCONx Conference
Format: Fireside chat and one-on-one investor meetings
Date: Tuesday, December 3, 2024
Time: 9:35 AM ET
Location: Coral Gables, FL
7Th 年度evercore healthconx會議
格式：爐邊聊天和一對一投資者會議
日期：2024年12月3日星期二
時間：東部時間上午9:35
地點：佛羅里達科勒爾蓋布爾斯
Piper Sandler 36th Annual Healthcare Conference
Format: Fireside chat and one-on-one investor meetings
Date: Wednesday, December 4, 2024
Time: 11:30 AM ET
Location: New York, NY
派傑投資 36樓 年度醫療保健會議
格式：爐邊聊天和一對一投資者會議
日期：2024年12月4日星期三
時間：美國東部時間上午11:30
地點：紐約，紐約州
A live webcast of the conference presentation will be available on the Investors section of the company's website at . An archived replay will be available for approximately 30 days following the presentation.
公司網站的投資者專區將提供會議演示的實時網絡直播。演示結束後，將提供約30天的存檔回放。
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company's innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
關於iteos therapeutics, inc。
iteos therapeutics是一家臨床階段的生物製藥公司，致力於開拓新一代免疫腫瘤學治療藥物的發現和開發。iteos therapeutics利用其對腫瘤免疫學和免疫抑制通路的深刻理解，設計新型候選藥物，有潛力恢復對癌症的免疫反應。公司創新的產品線包括三個臨床階段項目，針對新穎的、經過驗證的免疫抑制通路，具有優化的藥理特性，以改善臨床結果，包括TIGIT/CD226通路和腺苷途徑。iteos therapeutics總部位於馬薩諸塞州的Watertown，在比利時的Gosselies設有研究中心。
Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at . The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.
信息的互聯網發佈
iteos定期在其網站「投資者」版塊發佈對投資者可能重要的信息。公司鼓勵投資者和潛在投資者定期訪問我們的網站，了解有關iteos的重要信息。
For further information, please contact:
如需更多信息，請聯繫：
Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com
投資者聯繫人：
Carl Mauch
iTeos治療公司
carl.mauch@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
媒體聯繫：
media@iteostherapeutics.com
譯文內容由第三人軟體翻譯。
